An Honest Assessment of Who It's Built For and Who Should Look Elsewhere Based on the publicly available information reviewed and the clinical evidence framework that applies to this category, here's a structured final assessment: Gala Health HRT may be worth discussing with a licensed provider if you: Are living with moderate-to-severe menopause symptoms - hot flashes, night sweats, sleep disruption, mood changes - that are significantly affecting your daily life Are under 60 or within 10 years of menopause onset - the timing window where evidence supports the strongest benefit-risk profile for HRT Don't have significant contraindications to HRT (cardiovascular history, blood clot history, history of hormone-sensitive cancers) - though a licensed provider must make this determination Have found traditional menopause care difficult to access, costly, or inconsistent in menopause-specific guidance Are comfortable with a fully online care model and understand the limitations of telehealth versus in-person evaluation Understand that a prescription isn't guaranteed and that your specific treatment plan depends entirely on a licensed provider's independent clinical assessment Are willing to ask the specific questions about cancellation, labs, and formulation choices before committing to a plan Consider in-person evaluation first if you: Have a complex medical history including cardiovascular conditions, a personal or strong family history of breast or other cancers, or active or prior blood clot history - these situations need in-person evaluation with a specialist Are past 60 or more than 10 years from menopause onset - the evidence picture for HRT at this stage is more nuanced and the risk-benefit calculation is different Are specifically seeking FDA-approved (non-compounded) HRT formulations and want the full regulatory assurance that comes with approved drug products Need a provider who can conduct a physical examination as part of your evaluation Have experienced significant adverse reactions to hormone therapy in the past Have not yet discussed HRT with any licensed clinician and have no baseline understanding of your own hormone levels or contraindications The 2025-2026 FDA labeling shift is real, significant, and worth knowing about if you've been avoiding HRT based on older warning language
Lean-mass preservation add-ons have emerged as a distinct innovation category
Milk Thistle
Kristensen, M., & Holst, J
